Beyond Aspergillus fumigatus: The Clinical Burden of Aspergillus flavus and Aspergillus niger in Chronic Pulmonary Diseases
Pathogens · 01.06.2026 · 15 (6) · 597
DOI: 10.3390/pathogens15060597 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathogens, online erschienen am 01.06.2026. Verfasst von Lisa Brizzolara und 10 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Chemistry Laboratory, Fondazione IRCCS San Gerardo Dei Tintori, Via Pergolesi 33, 20900 Monza, Italy. Hauptthemen laut MEDLINE: Aspergillus niger, Aspergillus flavus, Aspergillosis, Lung Diseases. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The clinical burden of pulmonary diseases associated with the genus Aspergillus is increasing, although diagnostic focus remains largely on A. fumigatus. This study evaluated the diagnostic value of testing for A. flavus and A. niger-specific IgG in patients with chronic respiratory conditions.
Methods
A retrospective study was conducted on 274 subjects (156 with chronic respiratory diseases, Bronchiectasis, Hypersensitivity Pneumonitis [HP], and Interstitial Lung Disease [ILD] non-HP, and 67 healthy controls). Cut-off values were established at the 97.5th percentile of the control group: 30 mg/L for A. fumigatus, 13 mg/L for A. flavus, and 8 mg/L for A. niger.
Results
Among 109 patients who tested negative for A. fumigatus, 49.5% showed positivity to at least one other species, preventing a significant diagnostic gap in exposure detection. Notably, 40.4% of these patients exhibited simultaneous positivity for both A. flavus and A. niger. In the HP subgroup, 100% of patients who were A. fumigatus-positive also showed concurrent positivity to the two other species. Furthermore, the Bronchiectasis group showed the highest rate of isolated A. flavus at 11.8%.
Conclusions
Testing solely for A. fumigatus IgG leads to substantial underestimation of Aspergillus exposure. Integrating A. flavus and A. niger into diagnostic panels is essential for a comprehensive immunological assessment of fungal interaction, particularly in HP and ILD, where identifying specific antigenic exposure is crucial for managing chronic inflammation and preventing disease progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Chemistry Laboratory, Fondazione IRCCS San Gerardo Dei Tintori, Via Pergolesi 33, 20900 Monza, Italy.
- School of Medicine and Surgery, University of Milano-Bicocca, 20126 Milano, Italy.
- Respiratory Diseases Unit, Fondazione IRCCS San Gerardo dei Tintori, 20900 Monza, Italy.
ORCID-Profile: Jari Intra, Paola Faverio, Nicoletta Novati, Fabrizio Luppi, Marialuisa Lavitrano, Marco Casati
Zitieren
APA
Brizzolara, L., Intra, J., Faverio, P., Biffi, A., Basta, F., Delfini, C., Novati, N., Zucchetti, E., Luppi, F., Lavitrano, M., & Casati, M. (2026). Beyond Aspergillus fumigatus: The Clinical Burden of Aspergillus flavus and Aspergillus niger in Chronic Pulmonary Diseases. Pathogens, 15(6), 597. https://doi.org/10.3390/pathogens15060597
Vancouver
Brizzolara L, Intra J, Faverio P, Biffi A, Basta F, Delfini C, et al. Beyond Aspergillus fumigatus: The Clinical Burden of Aspergillus flavus and Aspergillus niger in Chronic Pulmonary Diseases. Pathogens. 2026;15(6):597. doi:10.3390/pathogens15060597
BibTeX
@article{Brizzolara2026,
author = {Brizzolara, Lisa and Intra, Jari and Faverio, Paola and Biffi, Alice and Basta, Francesca and Delfini, Cristina and Novati, Nicoletta and Zucchetti, Elisa and Luppi, Fabrizio and Lavitrano, Marialuisa and Casati, Marco},
title = {Beyond Aspergillus fumigatus: The Clinical Burden of Aspergillus flavus and Aspergillus niger in Chronic Pulmonary Diseases},
journal = {Pathogens},
year = {2026},
volume = {15},
number = {6},
pages = {597},
doi = {10.3390/pathogens15060597}
}
EUVIMED